Effects of pembrolizumab combined with synchronous radiotherapy and chemotherapy on tumor markers and immune balance in patients with advanced non-small cell lung cancer
Objective To observe the application effect of pembrolizumab combined with synchronous radiotherapy and chemotherapy in the clinical treatment of advanced non-small cell lung cancer.Methods A total of 110 patients with advanced non-small cell lung cancer admitted to Xi'an International Medical Center Hospital from December 2021 to December 2023 were selected and randomly divided into two groups,each with 55 cases.The control group received synchronous radiotherapy and chemotherapy,while the study group received combined treatment with pembrolizumab on the basis of the control group.The application effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P＜0.05).The levels of cytokeratin 21-1 fragment(CYFRA21-1),vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125),and carcinoembryonic antigen(CEA)in the study group were lower than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The study group had higher quality of life(FACT-L)and Karl Fischer's(KPS)scores than the control group,and the median progression free survival was longer than the control group(P＜0.05).The levels of CD3+and CD4+in the study group were higher than those in the control group,while the levels of CD8+were lower than that in the control group(P＜0.05).Conclusion In the clinical treatment of advanced non-small cell lung cancer,the combination of pembrolizumab and synchronous radiotherapy and chemotherapy can effectively alleviate the high expression of tumor markers,improve the quality of life of patients,correct immune balance,and have high practicality and safety.
Advanced non-small cell lung cancerPabolizumabSynchronous radiotherapy and chemotherapyTumor markers
万方数据
维普
